The Globe and Mail27d
Clearside Biomedical Announces Successful End-of-Phase 2 Meeting with the FDA and Alignment on Phase 3 Plans for Suprachoroidal CLS-AX in Wet AMD
“We are pleased to report the positive outcome of our End-of-Phase 2 meeting with the FDA,” said George Lasezkay, PharmD, JD, President and Chief Executive Officer. “With a positive safety ...
Morningstar27d
Biodexa Announces Successful Outcome of a Type C Meeting with FDA Regarding the Phase 3 Program for eRapa in FAP
The Type C meeting followed a productive End of Phase 2 meeting with FDA and the publication of Phase 2 data of eRapa in FAP at six months at Digestive Disease Week in May 2024 and 12 months data ...
Seeking Alpha5d
Connect Biopharma Announces Publication of Positive Data from Global Phase 2 Trial of Rademikibart in Patients with Moderate-to-Severe Uncontrolled Asthma
Connect Biopharma previously received agreement from the U.S. Food and Drug Administration in an end-of-Phase 2 meeting with the Division of Pulmonology, Allergy, and Critical Care, in the Office ...
Clearside Biomedical, Inc.: Clearside Biomedical Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
Successful End-of-Phase 2 Meeting with FDA Results in Alignment on Phase 3 Plans for CLS-AX in Wet AMD - - Asia-Pacific Partner's New Drug Application for ARCATUS® (XIPERE®) for Uveitic Macular Edema ...